Michael W. Pride - Concepedia

Author

Michael W. Pride

Also Known As

F. Palmen, Kunle Odunsi, M PRIDE, M Pride, M W Pride, M. Pride, M. W. PRIDE*, M. W. Pride, MICHAEL W. PRIDE, Michael Pride

101

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Pfizer (United Kingdom)The University of Texas MD Anderson Cancer Center Pearl River Community College Roswell Park Comprehensive Cancer Center

About

Michael W. Pride is an author at Pfizer (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.7K
2	Allergy	2	2	84
3	Engineering	1	1	32
4	Health Sciences	1	1	121
5	Public Health	1	1	68

Michael W. Pride

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults Marc J. M. Bonten, Susanne M. Huijts, Marieke Bolkenbaas, New England Journal of Medicine	2015	1.2K
BNT162b vaccines protect rhesus macaques from SARS-CoV-2 Annette B. Vogel, Isis Kanevsky, Ye Che, Nature VaccinationBnt162b VaccinesVaccine DevelopmentVaccine TargetImmunology	2021	725
Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children Bruce D. Forrest, Michael W. Pride, Andrew J. Dunning, Clinical and Vaccine Immunology	2008	251
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease Han-Qing Jiang, Susan K. Hoiseth, Shannon L. Harris, Vaccine VaccinationVaccine DevelopmentVaccine TargetImmunologyInfection Control	2010	198
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age Donald Hurley, Carl Griffin, Mariano Young, Clinical Infectious Diseases	2020	156
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years Brandon Essink, Charu Sabharwal, Kevin Cannon, Clinical Infectious Diseases	2021	154
A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates Annette B. Vogel, Isis Kanevsky, Ye Che, VaccinationVaccine DevelopmentPrevents Lung InfectionVaccine ResearchImmunology	2020	138
Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine Michael W. Pride, Susanne M. Huijts, Kangjian Wu, Clinical and Vaccine Immunology Klebsiella PneumoniaeImmunologyImmunodiagnostic AssayDrug ResistanceSerologic Testing	2012	121
Origin and Characteristics of Ultraviolet-B Radiation-Induced Suppressor T Lymphocytes Vijay Shreedhar, Michael W. Pride, Yan Sun, The Journal of Immunology Cutaneous ExposureUv RadiationAutoimmune DiseaseLymphocyte DevelopmentPhotocarcinogenesis	1998	102
Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged >=50 Years With Community-Acquired Pneumonia Robert Sherwin, Sharon Gray, Ronika Alexander, The Journal of Infectious Diseases	2013	95

Page 1